Search

A study conducted in Zhejiang, People's Republic of China, focused on the efficacy of neutrophil membrane nanovesicles (NMNVs) in treating acute kidney injury caused by sepsis (S-AKI). The research involved testing the effects of NMNVs on renal function indicators in plasma, oxidative stress factors, and inflammatory factors in rats. The study concluded that NMNVs significantly reduced various indicators, effectively controlling disease progression in S-AKI. The research has been peer-reviewed and provides valuable insights into potential treatments for acute kidney injury. [Extracted from the article]

Researchers at SRM Institute of Science and Technology in Tamil Nadu, India, have published new findings on critical limb ischemia/peripheral artery disease, highlighting the need for innovative therapeutic strategies to address this complex vascular condition. The study explores the potential of cell-derived extracellular vesicles and artificial nanovesicles as promising avenues for therapeutic intervention, carrying bioactive cargo that can aid in tissue repair and angiogenesis. The research emphasizes the evolving landscape of CLI revascularization and the potential of groundbreaking vesicle therapies to revolutionize treatment paradigms in this field. [Extracted from the article]

A recent study conducted by Yonsei University in Seoul, South Korea, focused on psychosocial programs to alleviate fertility-related distress in cancer patients. The study included a systematic review of eight studies, combining quantitative and qualitative data to identify key components of effective interventions. The findings emphasized the importance of tailored interventions to meet the specific needs of patients, aiming to improve psychosocial outcomes and support long-term self-management of fertility-related issues. This research underscores the need for carefully designed psychosocial interventions to prevent negative emotional impacts and address unmet needs in cancer patients facing fertility issues. [Extracted from the article]

A patent has been issued to Bexion Pharmaceuticals Inc. for pharmaceutical compositions and methods of treating cancer using saposin C. The compositions include a polypeptide, phosphatidylserine lipid, buffer, trehalose, and water, with specific concentrations and ratios outlined. The method involves administering the composition to cancer patients, including those with solid tumors like glioma, ependymoma, or gastrointestinal cancer, intravenously over multiple cycles. The patent details the specific components and dosages required for effective treatment. [Extracted from the article]

A recent study published by researchers from the Pharmaceutics and Industrial Pharmacy Department focuses on enhancing the therapeutic effect and bioavailability of irradiated silver nanoparticle-capped chitosan-coated rosuvastatin calcium nanovesicles for the treatment of liver cancer. The study involved the fabrication of a novel chitosan-coated optimized formulation capped with irradiated silver nanoparticles to boost the anti-malignant impact of rosuvastatin calcium. The researchers found that the novel formulation showed a significant inhibition effect on carcinoma cells and could potentially improve oral bioavailability and enhance hepatic carcinoma recovery. For more information, the full article can be accessed for free at the publisher's website. [Extracted from the article]

A recent study from Anhui Medical University in China explores the use of engineered nanovesicles for co-delivery of glucose oxidase (GOX) and ferrocene to induce synergistic anti-tumor effects. The research aims to enhance the mortality of GOX by developing a strategy with high tumor targeting specificity. The study demonstrates that the engineered nanovesicles platform efficiently encapsulates GOX and ferrocene, achieving precise anti-tumor immunotherapy and significant inhibition of tumor growth. This work provides a smart nanovesicle platform for achieving precise and safe synergistic anti-tumor therapy, offering promising advancements in cancer treatment. [Extracted from the article]

Researchers at Wuhan University in China have developed a new immunotherapeutic nanomedicine using tea leaf-derived nanovesicles to enhance immunotherapy against head and neck squamous carcinoma. The nanovesicles, loaded with a chemotherapeutic drug and ferric ions, trigger immunogenic cell death and macrophage reprogramming to boost the immune response against cancer. This innovative approach shows promise for future clinical applications and has been peer-reviewed. For more information, readers can refer to the Chemical Engineering Journal. [Extracted from the article]

Researchers from Zhengzhou University in China have developed a biomimetic nanovesicle platform called P-PAM/MLN for targeted delivery of the anticancer drug MLN4924. This platform utilizes platelet membrane vesicles to enhance tumor affinity and reduce off-target toxicity. The nanovesicles selectively release the drug in response to the acidic microenvironment of lysosomal compartments, effectively inhibiting tumor progression with minimal toxicity. This study provides a promising approach for delivering small molecule drugs to tumor tissues and offers insights for combining nanocarriers with clinical drugs. [Extracted from the article]

A patent application titled "Biomarkers Of Megakaryocyte-Derived Extracellular Vesicles" has been published online, highlighting compositions and methods related to manufactured megakaryocyte-derived extracellular vesicles. These vesicles demonstrate a unique biomarker profile suitable for therapeutic delivery and treating various diseases, including genetic disorders, infectious diseases, and hematopoietic disorders. The application outlines the use of these vesicles for drug delivery, gene replacement therapy, and gene-editing, emphasizing the potential for enhanced cargo packaging and delivery to cells. [Extracted from the article]

The patent application titled "Methods Related To Megakaryocyte-Derived Extracellular Vesicles" discusses innovative methods for generating and purifying extracellular vesicles derived from human pluripotent stem cells. These methods aim to enhance cargo packaging and delivery to cells, providing a cost-effective and efficient approach to therapeutic applications. By isolating these vesicles from megakaryocytes, researchers can potentially improve drug delivery systems and gene therapy techniques. The patent application highlights the importance of viability and timing in the differentiation process for optimal results. [Extracted from the article]

A recent study from Chongqing Medical University in China explores the use of neurotransmitter-mimicking nanovesicles for postoperative treatment of glioblastoma stem cells to prevent tumor recurrence. The research focuses on the challenges of targeting residual glioblastoma stem cells after surgery and introduces a nanovesicle that specifically targets these cells, potentially reducing the risk of tumor recurrence. This innovative approach shows promise in providing a more effective treatment for glioblastomas and highlights the importance of emerging technologies in oncology research. [Extracted from the article]

The article discusses the use of milk-derived nanovesicles loaded with Connexin 43 peptides for targeted cardiac ischemia-reperfusion therapy. These engineered nanovesicles have shown remarkable injury targeting capabilities, with significant reductions in infarct size and preservation of heart function in a mouse model of ischemia-reperfusion injury when orally administered after myocardial infarction. The study highlights the potential of utilizing naturally occurring milk-derived extracellular vesicles as an oral delivery system for therapeutic peptides, achieving unprecedented targeting efficiency and efficacy in treating myocardial ischemia-reperfusion injury. [Extracted from the article]

Researchers from the Department of Science in Rome, Italy, have published a study on the use of liposomes for delivering antioxidants to the skin to combat oxidative stress and skin damage. The study highlights the importance of antioxidants in neutralizing reactive oxygen species and preserving skin health. Liposomal formulations offer advantages such as improved stability, controlled release, and enhanced penetration through the skin barrier, making them a promising tool for skin health applications. The research provides an overview of emerging trends in liposomal delivery systems for antioxidants and compares various delivery systems for common antioxidants. [Extracted from the article]

Researchers at Sinai University conducted a study on nanovesicles to improve the dissolution, bioavailability, and pharmacokinetic behavior of famotidine, a histamine H2 receptor antagonist. The study focused on utilizing spanlastics, a nano, surfactant-based drug delivery system, to enhance the solubility and delivery of famotidine. The optimal spanlastic formulation showed promising characteristics such as small particle size, high entrapment efficiency, and enhanced drug release, resulting in improved pharmacokinetic behavior. This research contributes to the development of innovative approaches in pharmaceuticals and nanotechnology. [Extracted from the article]

Researchers from Tianjin University of Traditional Chinese Medicine have developed ginger-derived nanovesicles loaded with curcumin for the treatment of colitis. The study demonstrated high loading capacity and encapsulation efficiency of curcumin in the nanovesicles, which showed superior anti-colitis activity in mice compared to curcumin alone. The research suggests that these nanovesicles have potential for enhanced therapeutic delivery of curcumin in the treatment of colitis. [Extracted from the article]

Researchers at the Department of Biomedical Engineering have developed an innovative approach using cell-derived nanovesicles engineered with chimeric antigen receptor (CAR) and hyaluronidase PH20 to enhance targeted photodynamic therapy for cancer. These engineered nanovesicles specifically target tumor cells expressing HER2 and improve tumor penetration and drug distribution in the tumor microenvironment. In vitro and in vivo experiments have shown increased reactive oxygen species generation, improved tumor retention, and enhanced therapeutic efficacy compared to conventional methods, offering a promising strategy for nanodrug-based cancer therapies with reduced side effects. [Extracted from the article]

Researchers from Ain Shams University in Cairo, Egypt, have developed novel ultra-deformable nano-vesicles to enhance dermal and transdermal drug delivery. These lipid-based nano-vesicles contain penetration enhancers to facilitate drug penetration through the skin. The study provides an overview of penetration enhancer containing vesicles (PEVs) and their therapeutic outcomes compared to conventional dosage forms. For more information, readers can access the full article in the Archives of Pharmaceutical Sciences by contacting the researchers listed. [Extracted from the article]

Researchers from Mazandaran University of Medical Sciences conducted a study on enhancing the skin absorption of propolis extract through niosomal nanovesicle formulation. The study focused on designing and optimizing novel formulations for transdermal delivery using nanoparticles. Results showed that the niosomal formulation significantly improved the permeability and skin absorption of propolis, indicating the potential of niosomes as effective carriers for herbal extracts. The study highlights the impact of cholesterol content, surfactant type, and ratio on the physicochemical properties and loading capacity of niosomes. [Extracted from the article]

A recent study from Chandigarh University in Punjab, India, explores the use of lactoferrin-conjugated extracellular nanovesicles (LF-EVs) as a targeted treatment for cellular melanoma. These nanovesicles show promise in enhancing cellular uptake, minimizing off-target effects, and promoting efficient drug release within melanoma cells. The research highlights the potential of LF-EVs to revolutionize melanoma treatment strategies, offering personalized and less invasive therapies for this aggressive form of skin cancer. [Extracted from the article]

A patent application titled "Cell-Derived Nanovesicles For In Vivo Transport And Delivery Of Therapeutic Materials" was published online by inventors from Stanford, CA. The invention focuses on nanovesicle compositions encapsulating therapeutic agents with a mean particle diameter of 90-500 nanometers, derived from various cell types including stem cells and tumor cells. These nanovesicles aim to improve drug delivery efficiency and biocompatibility for potential clinical applications in treating diseases such as cancer. The patent application highlights the use of recombinant membrane-associated proteins, antibodies, affibodies, and peptides on the nanovesicles' external surface to enhance targeting capabilities. [Extracted from the article]

Researchers from Kangwon National University in South Korea have discovered that extracellular nanovesicles derived from gold kiwi can protect bone marrow mesenchymal stem cells (BM-MSCs) from ultraviolet-induced photoaging. These nanovesicles help alleviate aging-related impairments in cellular functions crucial for bone homeostasis by reducing intracellular reactive oxygen species levels and enhancing osteoblast differentiation. The findings suggest that gold kiwi-derived nanovesicles could be a promising biomaterial for treating bone-related diseases like osteoporosis. The study was funded by the Ministry of Science and The ICT and Ottogi Ham Taiho Foundation. [Extracted from the article]

Researchers from Tohoku University have conducted a study on the effects of matrix-bounded nanovesicles from high-hydrostatic pressure decellularized tissues on neural regeneration. The study aimed to extract bioactive factors from decellularized brain and placenta tissues prepared by HHP decellularization and evaluate their effects on nerve regeneration. The results showed that these factors can be extracted and have positive effects on processes such as neurite outgrowth and nerve fiber repair. This research provides valuable insights into the potential use of nanovesicles for tissue regeneration. [Extracted from the article]

A study conducted at Xiamen University in the People's Republic of China explores the potential of macrophage efferocytosis in immunotherapy for atherosclerosis. Researchers developed a biomimetic nanorobot, UM-EVLipo, which utilizes a two-pronged strategy to activate macrophage efferocytosis and reduce plaque area in cardiovascular disease. The nanorobot, which combines nano-motor and extracellular vesicles, shows promise in preventing atherosclerotic cardiovascular disease. The study was funded by various organizations and has been peer-reviewed. [Extracted from the article]

Researchers at the University of Arizona have conducted a study on olive-derived lipid nanovesicles for drug delivery applications. These nanovesicles were found to have promising potential as a drug delivery system due to their physical and biological characteristics. The study demonstrated that olive-derived nanovesicles were stable under various physical and chemical stresses, showed good stability in harsh environments, and improved the efficacy of anticancer drugs. This research suggests that olive-derived nanovesicles could be a valuable candidate for drug nanocarriers in clinical applications. [Extracted from the article]

A study from Huazhong University of Science and Technology in Wuhan, China, explores the use of ROS-responsive biomimetic nanovesicles for targeted therapy of atherosclerosis. The research focuses on delivering rapamycin to plaque lesions to reduce inflammation, foam cell formation, and macrophage proliferation. This innovative approach shows promise in combating atherosclerosis by leveraging the characteristics of the plaque microenvironment. [Extracted from the article]

A new study from Nanjing Medical University in Jiangsu, China, explores the use of engineered nanovesicles loaded with docosahexaenoic acid (DHA) to synergize ferroptosis and immune activation for treating hepatocellular carcinoma. The research focuses on the potential of these nanovesicles to deliver DHA efficiently to tumor cells, induce ferroptosis, and activate immune cells in the tumor microenvironment. The study suggests that this approach, combining ferroptosis and immunomodulation, could complement traditional cancer treatments effectively. [Extracted from the article]

Researchers at Shenzhen University in China have discovered that clam-derived exosome-like nanovesicles (CENs) can alleviate alcohol-induced liver injury by improving mitochondrial function. These nanovesicles were found to carry functional lipids and proteins, survive in the gastrointestinal environment, and accumulate in the liver after oral administration. The study suggests that CENs could be a novel functional ingredient for managing alcoholic liver disease, as they effectively restored mitochondrial function and reduced hepatocyte death in mice. This research has been peer-reviewed and offers promising insights into potential hepatoprotective properties of CENs. [Extracted from the article]

Researchers at the University of Science and Technology in Wuhan, China, have developed a novel bioactive delivery system for diabetic wound treatment. The system involves biomimetic nanovesicles that enhance angiogenesis, antioxidant, and antibacterial activities. This innovative approach shows promise in improving the therapeutic efficacy for diabetic wounds. The study was supported by the National Natural Science Foundation of China and published in Materials Today Bio. [Extracted from the article]

Researchers at the Institute for Atherosclerosis Research have highlighted the role of pathogenic bacterial extracellular membrane nanovesicles (BEMNs) in triggering inflammation and atherogenesis, key processes in atherosclerotic cardiovascular disease (ASCVD). They suggest that bioengineered BEMNs loaded with specific drugs could serve as an effective targeted drug delivery system for treating ASCVD. This study explores the potential of nanomedicine methods using BEMNs and nanoparticles (NPs) as vehicles for drug delivery in ASCVD therapy. The research was supported by the Russian Science Foundation and the Ministry of Science And Highereducation of The Russian Federation. [Extracted from the article]

Researchers at the Universidad Autonoma de Guerrero have conducted a study on the role of kiwifruit in inhibiting carcinogenesis, focusing on its potential anticancer and anti-metastatic effects in cell culture studies and xenografted mice. The study highlights the pharmacological targeting of oncogenic proteins by kiwifruit and the investigation of kiwifruit-derived nanovesicles as delivery vehicles for cancer prevention. The research suggests that kiwifruit extracts and bioactive molecules may regulate critical pathways involved in preventing carcinogenesis and metastasis. For more information, readers can access the full article in Postepy Higieny i Medycyny Doswiadczalnej. [Extracted from the article]

Researchers at Mayo Clinic Florida have developed novel EpCAM-binding aptamers for targeted delivery of RNA therapeutics. These aptamers, PLD01 and PLD02, were designed using an in silico approach and showed high affinity for EpCAM+ CCA cells. The modified aptamers were successfully incorporated into milk-derived nanovesicles, enabling targeted delivery of therapeutic cargo to EpCAM-expressing cells. This research highlights the potential of EpCAM-targeting aptamers in directing theranostic agents to specific cell types, particularly in cancer treatment. [Extracted from the article]

A recent study conducted at the University of Pavia in Italy focused on the development and biological characterization of cancer biomimetic membrane nanovesicles for enhancing therapy efficacy in human glioblastoma cells. These biomimetic nanovesicles, derived from cell membranes, showed improved biocompatibility, target specificity, and minimal immune responses. The research demonstrated that these nanovesicles effectively delivered therapeutic molecules and induced cytotoxic effects in human glioblastoma cells, making them a promising strategy for therapeutic applications. For more information, the full article can be accessed for free at the publisher's website. [Extracted from the article]

A study from Taizhou, China, discusses the use of engineered hybrid nanovesicles for enhanced cancer immunotherapy in melanoma. The research focuses on the development of nanovesicles adorned with specific receptors to target melanoma cells and stimulate an antitumor immune response. The study highlights the potential of these nanovesicles as effective immune checkpoint inhibitors for cancer treatment. For more information, the full article can be accessed for free online. [Extracted from the article]

Researchers from Soochow University in Suzhou, China, have developed room-temperature-stable immunosuppressive nanovesicles enriched with programmed cell death-ligand 1 (PD-L1@NV) to mitigate T cell-driven immunopathology post-myocardial infarction. These nanovesicles effectively bind to T cell membranes, suppressing proliferation and inducing exhaustion in activated CD8 T lymphocytes, supporting myocardial tissue recovery. The study highlights a scalable and secure strategy for myocardial infarction treatment by reshaping T cell dynamics. This research was funded by various organizations and has been peer-reviewed, offering valuable insights into emerging technologies in cardiology and immunology. [Extracted from the article]

A recent study conducted at I. M. Sechenov First Moscow State Medical University explored the therapeutic potential of exosomes and matrix-bound nanovesicles from human umbilical cord mesenchymal stromal cells in treating osteoarthritis. The research found that both types of extracellular vesicles showed promise in reducing inflammation and degenerative processes in joints, with exosomes demonstrating superior results in preserving cartilage and reducing synovitis. These findings suggest that exosomes derived from umbilical cord mesenchymal stromal cells could be a promising therapeutic option for osteoarthritis by modulating inflammation and promoting joint tissue regeneration. [Extracted from the article]

A recent study conducted at University Hospital in Quebec City, Canada, focused on the effects of ruminant trans fatty acids on inflammation and glucose metabolism in adipose tissue. The research found that trans-palmitoleic acid (TPA) had a distinct impact on inflammation and diabetes-related pathways compared to elaidic acid (EA). This study was supported by various research councils and has been peer-reviewed, providing valuable insights into the relationship between fatty acids and metabolic diseases. [Extracted from the article]

A research study from the University of Pittsburgh School of Medicine explores the use of a combination of a statin (fluvastatin) and Matrix-Bound Nanovesicles (MBV) to enhance optic nerve regeneration by modulating inflammation. The study demonstrates that this combination promotes infiltration of monocytes and neutrophils, leading to retinal ganglion cell (RGC) protection and axon regeneration. The research provides novel insights into the development of immunomodulatory regenerative therapy for nerve injuries. [Extracted from the article]

Researchers at the University of Pittsburgh have conducted a study on osteolysis, a condition characterized by inflammation and bone destruction around orthopedic implants. The study focused on the use of matrix-bound nanovesicles (MBVs) to mitigate inflammation and prevent osteolysis. Results showed that MBVs suppressed osteoclast formation and activity, suggesting that they could be a potential therapeutic option for preventing periprosthetic loosening. The research was published in Science Advances and can be accessed for free online. [Extracted from the article]

Researchers at Zhejiang University in Hangzhou, China, have developed a nanovesicle-templated nanogel called PCG-Fe/DHA that delivers iron and dihydroartemisinin (DHA) for ferroptosis cancer therapy. This nanogel disrupts intracellular iron homeostasis, leading to increased ferroptosis of tumor cells and enhanced tumor inhibition in mice. Additionally, the PCG-Fe/DHA nanogel can target tumors and provide MRI-guided tumor diagnosis, making it a promising dual-modal strategy for cancer therapy. The research has been peer-reviewed and published in the Chemical Engineering Journal. [Extracted from the article]

A patent application titled "Pressurized Nanoemulsion" was published online by inventors from Leverkusen, Germany. The application describes a formulation involving nanoemulsions stored in pressurized containers, which can be released as foam or spray for topical treatments. The invention aims to stabilize nanoemulsions under various conditions, enhancing their stability and effectiveness in pharmaceutical and cosmetic compositions. The patent application outlines specific aspects of the formulation, method, and use of pressurized nanoemulsions for various applications, including medicine and cosmetics. [Extracted from the article]

Researchers from Xiamen University in the People's Republic of China have developed a novel biomimetic nanomedicine, AMV@NanoCip, to target methicillin-resistant Staphylococcus aureus (MRSA) in lower respiratory tract infections. This innovative therapy combines PBP2a antibody-presenting nanovesicles with self-assembled ciprofloxacin nanoparticles exhibiting sonodynamic properties, achieving significant antibacterial efficacy. The sequential treatment strategy of adhesion, membrane disruption, and synergistic therapy shows promise in combating bacterial infections, as demonstrated in in vitro and in vivo models. This research has been peer-reviewed and offers a new approach to addressing the global health concern of bacterial-induced lung infections. [Extracted from the article]